Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

Also called NCT05131139

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05131139
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05131139. Allocation not applicable; no masking; primary purpose diagnostic. Start 2021-10-20 (actual); primary completion 2025-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
Condition
Diabetes Mellitus
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
Continuous Glucose Monitoring System
Lead sponsor
Senseonics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05131139
Content hash
0315fec18485cd653751d3a80071c21ed91c3b7d387ed8890de6d706a83eb0a3